Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN
Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN
Apellis Pharmicals 和 Sobi 宣佈 Pegcetacoplan 針對 C3 腎小球病 (C3G) 和 IC-MPGN 移植後復發的 Pegcetacoplan 的 2 期 NOBLE 研究爲期一年的積極結果
- Rapid reduction in disease activity seen at 12 weeks was sustained at one year
- 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared
- Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress
- 在12周時出現的疾病活動迅速減少持續一年
- 55% 的患者表現出 C3c 染色強度爲零，這表明 C3c 沉積物已被清除
- 在歐洲腎臟協會（ERA）大會上以最新口頭陳述的形式亮相
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。